Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report)'s stock price rose 4.9% on Friday. The stock traded as high as $16.08 and last traded at $16.5490. 96,512 shares were traded during trading, a decline of 93% from the average daily volume of 1,411,621 shares. The stock had previously closed at $15.78.
Analysts Set New Price Targets
Several analysts recently weighed in on the stock. TD Cowen started coverage on shares of Arcus Biosciences in a research note on Wednesday, September 16th. They issued a "buy" rating on the stock. Morgan Stanley set a $23.00 price objective on Arcus Biosciences in a research report on Monday, August 10th. Wells Fargo & Company upped their target price on Arcus Biosciences from $23.00 to $26.00 and gave the company an "equal weight" rating in a report on Thursday, August 6th. William Blair began coverage on shares of Arcus Biosciences in a research report on Friday, October 16th. They set an "outperform" rating for the company. Finally, Wedbush dropped their price target on shares of Arcus Biosciences from $49.00 to $45.00 and set an "outperform" rating on the stock in a research report on Thursday, November 5th. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $39.36.
Read Our Latest Analysis on RCUS
Arcus Biosciences Stock Performance
The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.34 and a current ratio of 3.34. The company has a 50 day moving average price of $21.65 and a 200 day moving average price of $24.33. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of -4.36 and a beta of 1.04.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.11). Arcus Biosciences had a negative return on equity of 91.65% and a negative net margin of 453.00%. The firm had revenue of $9.00 million for the quarter, compared to analyst estimates of $7.58 million. During the same period last year, the company posted ($1.27) earnings per share. The firm's quarterly revenue was down 65.4% compared to the same quarter last year. Equities research analysts predict that Arcus Biosciences, Inc. will post -3.49 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Arcus Biosciences
Hedge funds and other institutional investors have recently made changes to their positions in the business. Integrated Wealth Concepts LLC bought a new position in Arcus Biosciences in the 2nd quarter valued at about $30,000. University of Texas Texas AM Investment Management Co. bought a new stake in Arcus Biosciences during the third quarter worth $45,000. KBC Group NV purchased a new stake in Arcus Biosciences in the 1st quarter valued at $50,000. Sterling Capital Management LLC lifted its stake in Arcus Biosciences by 328.4% during the 3rd quarter. Sterling Capital Management LLC now owns 2,716 shares of the company's stock valued at $70,000 after acquiring an additional 2,082 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its holdings in Arcus Biosciences by 47.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 2,937 shares of the company's stock worth $76,000 after acquiring an additional 947 shares during the last quarter. 92.89% of the stock is owned by institutional investors.
Arcus Biosciences Company Profile
(
Get Free Report)
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2015 and headquartered in Hayward, California, the company researches therapies that target immune pathways and other processes involved in tumor growth. Its pipeline consists of investigational medicines, including antibody and small-molecule candidates designed to be used alone or in combination. Arcus's research has focused on areas such as checkpoint inhibition and the adenosine pathway; its candidates are under clinical development and are not established treatments.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arcus Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.
While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.